Status:
COMPLETED
Adjunctive Glycine for Obsessive Compulsive Disorder
Lead Sponsor:
Nathan Kline Institute for Psychiatric Research
Collaborating Sponsors:
Obsessive Compulsive Foundation
Conditions:
Obsessive Compulsive Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
The purpose of this study is to determine whether individuals with obsessive compulsive disorder who will take a preparation of the amino acid glycine in addition to their current treatment, may exper...
Detailed Description
Individuals with obsessive compulsive disorder (OCD) often find inadequate relief, even with the best of currently available treatments. Some evidence suggests the the neurotransmitter glutamate may b...
Eligibility Criteria
Inclusion
- Diagnosis of OCD present for at least 1 year
- Male or female, age 18 to 65
- Stable medication regimen for 12 weeks prior to study entry
- at least moderately severe OC symptoms
Exclusion
- Active substance use disorder within the last 6 months
- Comorbid schizophrenia, schizoaffective disorder, bipolar disorder, tic disorder, Tourette Disorder, schizotypal personality disorder
- Hoarding as the principal OCD symptom
- Insulin-dependent diabetes mellitus
- Pregnant or breastfeeding
Key Trial Info
Start Date :
June 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2006
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT00405535
Start Date
June 1 2004
End Date
December 1 2006
Last Update
December 16 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
The Nathan Kline Institute for Psychiatric Research
Orangeburg, New York, United States, 10962